Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06324461 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery

Study acronym: GLUMINS
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria shortened, about 3 wordsv4
  2. Primary completion date: Dec 31, 2026 to Dec 31, 2028
    • Study sites: 1 to 3
    • Study completion date: Dec 31, 2027 to Dec 31, 2028
    • Eligibility criteria revised
    v3
  3. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Interventions: Semaglutide 0.25mg subcutaneous injection (Drug) to Dulaglutide 0.75mg subcutaneous injection (Drug)
    • Eligibility criteria shortened, about 7 words
    • Site details revised
    • Collaborators expanded, about 5 words
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an investigator initiated, multi-center, open-labelled, superiority randomized controlled trial of 372 patients undergoing elective non-cardiac surgery. Recruited patients will be randomized in a 2:1 ratio to receive single subcutaneous dose of Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RAs) 1 to 14 days prior to surgery or receive routine care. Dulaglutide (Trulicity; Eli Lilly, USA) is chosen as GLP-1 Receptor Agonists investigational drug for this study. Apart from peri-operative routine care, all recruited subjects will undergo physical, respiratory and cardiac assessments including electrocardiography and blood check including cardiac enzymes. Myocardial injury, cardiovascular outcomes and safety will be assessed and evaluated for efficacy and safety of this prophylactic measurement for the reduction of myocardial injury after non-cardiac surgery.
Trial Details
NCT Number NCT06324461
Lead Sponsor The University of Hong Kong
Collaborators: Research Grants Council, Hong Kong
Conditions
(from sponsor)		 Myocardial Injury
Enrollment 372 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov